NCT00115648View on ClinicalTrials.gov

Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission

PHASE3CompletedINTERVENTIONAL
Enrollment

3,300

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

August 31, 2007

Study Completion Date

October 31, 2009

Conditions
HIV Infections
Interventions
DRUG

Nevirapine

Oral NVP daily dosage

DRUG

AZT

Oral AZT daily

DRUG

NVP and AZT

Oral single dose NVP plus oral daily AZT during the first weeks

DRUG

NVP

Oral NVP daily to age 14 weeks

DRUG

NVP+AZT

Oral NVP daily plus oral AZT daly to age 14 weeks

Trial Locations (1)

1331

College of Medicine, Blantyre

All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Johns Hopkins Bloomberg School of Public Health

OTHER

NCT00115648 - Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission | Biotech Hunter | Biotech Hunter